Direct Oral Anticoagulants after Ischemic Stroke: Which Patient? Which Drug? And How Early?

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation (AF) increases ischemic stroke risk.
• Vitamin K antagonists (VKAs) have been traditional anticoagulants.
• Direct oral anticoagulants (DOACs) offer an alternative with a potentially better safety profile.

Purpose of the Study:

• To review the clinical use of DOACs in patients with AF and ischemic stroke.
• To discuss challenges in DOAC therapy, including timing, dosing, and comparative effectiveness.
• To outline the role of DOACs in non-AF ischemic stroke and review risks associated with reversal agents and pausing therapy.

Main Methods:

• Literature review of randomized clinical trials and comparative evidence.
• Analysis of clinical guidelines and expert recommendations.
• Synthesis of data on DOAC efficacy, safety, and management strategies.

Main Results:

• DOACs demonstrate lower bleeding and mortality rates compared to VKAs in AF patients with ischemic stroke.
• Key clinical considerations include optimal timing for DOAC initiation, appropriate dosing, and understanding comparative data across different DOACs.
• DOACs are also relevant for non-AF ischemic stroke patients, with specific risks noted for reversal agents and treatment interruption.

Conclusions:

• DOACs represent a significant advancement in anticoagulation for AF patients experiencing ischemic stroke.
• Careful consideration of clinical challenges and patient-specific factors is crucial for optimizing DOAC therapy.
• Further research and ongoing trials will continue to refine the role of DOACs in stroke prevention and management.